WS
TPST icon

Wedbush Securities’s Tempest Therapeutics TPST Stock Holding History

Wedbush Securities’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-74
Closed -$23K – 972
2020
Q3 		$23K Sell
74
-3
-4% -$1.02K ﹤0.01% 918
2020
Q2 		$26K Buy
77
+13
+20% +$5.19K ﹤0.01% 937
2020
Q1 		$66K Buy
+64
New +$93.3K 0.01% 808
2018
Q2 		– Sell
-14
Closed -$34K – 908
2018
Q1 		$34K Buy
+14
New +$42K ﹤0.01% 798
2017
Q3 		– Sell
-4
Closed -$19K – 871
2017
Q2 		$19K Hold
4
– – ﹤0.01% 827
2017
Q1 		$23K Sell
4
-5
-56% -$23.3K ﹤0.01% 826
2016
Q4 		$42K Buy
+9
New +$112K 0.01% 787
2016
Q3 		– Sell
-4
Closed -$58K – 860
2016
Q2 		$58K Buy
+4
New +$91.4K 0.01% 723
2015
Q4 		– Sell
-3
Closed -$87K – 775
2015
Q3 		$87K Sell
3
-2
-40% -$135K 0.02% 631
2015
Q2 		$454K Hold
5
– – 0.08% 283
2015
Q1 		$505K Buy
+5
New +$666K 0.09% 279

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wedbush Securities's TPST Position: Q4 2020 in Review

Wedbush Securities sold out of Tempest Therapeutics (TPST) in Q4 2020, closing a stake of 74 shares — an estimated $23K sold.

Wedbush Securities first reported a position in TPST in Q1 2015 and held it in 11 quarters. The position peaked at $505K in Q1 2015. 37 funds tracked by Wall St. Rank hold TPST as of Q4 2020.

  • Wedbush Securities reported no remaining Tempest Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 74 Tempest Therapeutics shares in Q4 2020, an estimated $23K.
  • Wedbush Securities first reported a position in Tempest Therapeutics in Q1 2015 and held it in 11 quarters.
  • Wedbush Securities's Tempest Therapeutics position peaked at $505K in Q1 2015.
  • 37 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.